Tumor growth inhibition of MDA-MB–231 estrogen independent human breast cancer by treatment with antagonist of LHRH Cetrorelix®

Introduction: The efficacy of endocrine therapy with agonists of luteinizing hormone releasing hormone (LHRH) in premenopausal women with estrogen dependent breast cancers is well established. The expression of LHRH and its receptor as part of an autocrine, paracrine regulatory mechanism of cell proliferation has been shown in various cancers, including breast cancer. In this study we investigated the direct effect of LHRH antagonist Cetrorelix® on estrogen independent human breast cancer cell line MDA-MB–231 xenografts. Materials and methods: The mRNA expression of LHRH-R was measured by PCR and LHRH-R protein…